Glaxosmithkline Pharmaceutical Profit & Loss Annual

BSE: 500660 | NSE: GLAXO | ISIN: INE159A01016 | Sector: Biotechnology & Drugs
3,271.10 -10.55 (-0.32%)Updated : 08 Jul 2025
Fiscal Period2025202420232022
Period End DateMar 25Mar 24Mar 23Mar 22
Total Operating Expense 2,636.372,778.002,513.912,599.03
Other Net 4.774.85-0.373.45
Diluted Weighted Average Shares 16.9416.9416.9416.94
Gain( Loss)on Saleof Assets 4.6920.589.6731.72
Depreciation/ Amortization 66.6669.5465.6268.04
Operating Income 1,112.84675.71737.81679.00
Net Income 927.58589.96610.691,694.72
Income Availableto Com Excl Extra Ord 927.58589.96607.64380.77
Other Operating Expenses Total 60.6461.0152.2447.06
Net Income Before Taxes 1,259.88816.19836.40779.05
Interest Exp( Inc) Net- Operating Total 0.130.140.140.14
Net Income After Taxes 927.58589.96607.64380.77
Income Availableto Com Incl Extra Ord 927.58589.96610.691,694.72
Costof Revenue Total 1,512.301,457.101,394.281,482.14
Gross Profit 2,236.911,996.611,857.441,795.89
Interest Inc( Exp) Net- Non- Op Total 137.58115.0589.2964.87
Diluted Net Income 927.58589.96610.691,694.72
DPS- Common Stock Primary Issue 42.0032.0032.0030.00
Provisionfor Income Taxes 332.30226.23228.76398.28
period Type ----
Net Income Before Extra Items 927.58589.96607.64380.77
Total Revenue 3,749.213,453.713,251.723,278.03
period Length 12.0012.0012.0012.00
Revenue 3,749.213,453.713,251.723,278.03
Selling/ General/ Admin Expenses Total 996.641,026.91991.00981.81
Diluted Normalized EPS 54.5540.9235.9122.13
Diluted EPS Excluding Extra Ord Items 54.7634.8335.8722.48
Total Extraordinary Items -0.003.041,313.95
Unusual Expense( Income) -163.3010.6119.82
*All figures in crores except per share values
Recommended For You
Trending Stocks
2,224.50+77.50(3.61%)
2,484.60+41.20(1.69%)
343.20+5.55(1.64%)
3,440.60-226.25 (-6.17%)
1,165.40-10.05 (-0.85%)